

# Maja Relja

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11952722/publications.pdf>

Version: 2024-02-01

15  
papers

413  
citations

840776

11  
h-index

1058476

14  
g-index

16  
all docs

16  
docs citations

16  
times ranked

509  
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. <i>Journal of Neural Transmission</i> , 2021, 128, 321-335.	2.8	37
2	Lack of Accredited Clinical Training in Movement Disorders in Europe, Egypt, and Tunisia. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1833-1843.	2.8	3
3	Update on the Management of Parkinson's Disease for General Neurologists. <i>Parkinson's Disease</i> , 2020, 2020, 1-13.	1.1	33
4	Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. <i>Journal of Neurology</i> , 2018, 265, 856-862.	3.6	51
5	Effect of botulinum toxin type-A treatment on non-motor symptoms and cognitive functions in patients with isolated adult-onset cervical dystonia. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-1-61.	0.0	0
6	Brainstem nuclei changes in migraine detected by transcranial sonography. <i>Neurological Sciences</i> , 2017, 38, 1509-1512.	1.9	5
7	When movement disorders hurt: Addressing pain in hyperkinetic disorders. <i>Parkinsonism and Related Disorders</i> , 2017, 44, 110-113.	2.2	12
8	Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. <i>Journal of Neurology</i> , 2017, 264, 112-120.	3.6	32
9	Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin. <i>Frontiers in Neurology</i> , 2017, 8, 35.	2.4	63
10	Strategies for treatment of dystonia. <i>Journal of Neural Transmission</i> , 2016, 123, 251-258.	2.8	31
11	Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. <i>Journal of Neurology</i> , 2015, 262, 2201-2213.	3.6	59
12	Clinical rating scales. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S229-S232.	2.2	6
13	A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2006, 248, 251-254.	0.6	21
14	Botulinum toxin in tension-type headache. <i>Journal of Neurology</i> , 2004, 251, 1-1.	3.6	20
15	Catabolism of Endogenous Dopamine in Peripheral Tissues: Is There an Independent Role for Dopamine in Peripheral Neurotransmission?. <i>Journal of Neurochemistry</i> , 1982, 38, 1453-1458.	3.9	40